Case ReportCase Report

Primary peritoneal carcinoma metastasizing to breast: a single case report and literature review from clinic to biology

Ji-Yuan Sun, Wondwossen Gebre, Yi-Min Dong, Xiao Shaun, Rachel Robbins and Alida Podrumar
Cancer Biology & Medicine September 2016, 13 (3) 389-395; DOI: https://doi.org/10.20892/j.issn.2095-3941.2016.0058

References

  1. 1.↵
    2. Dalrymple JC,
    3. Bannatyne P,
    4. Russell P,
    5. Solomon HJ,
    6. Tattersall MH,
    7. Atkinson K, et al.
    Extraovarian peritoneal serous papillary carcinoma: a clinicopathologic study of 31 case. Cancer. 1989; 64: 110–5.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    2. Ifthikar AM,
    3. Rathod PS,
    4. Shruthi S,
    5. Pallavi VR,
    6. Shobha K,
    7. Shankaranand B, et al.
    Primary peritoneal carcinoma: Regional cancer institute experience. Indian J Surg Oncol. 2014; 5: 232–6.
    OpenUrl
  3. 3.↵
    2. Parmley TH,
    3. Woodruff JD.
    The ovarian mesothelioma. Am J Obstet Gynecol. 1974; 120: 234–41.
    OpenUrlPubMedWeb of Science
  4. 4.↵
    2. Fromm GL,
    3. Gershenson DM,
    4. Silva EG.
    Papillary serous carcinoma of the peritoneum. Obstet Gynecol. 1990; 75: 89–95.
    OpenUrlPubMedWeb of Science
  5. 5.↵
    2. Altaras MM,
    3. Aviram R,
    4. Cohen I,
    5. Cordoba M,
    6. Weiss E,
    7. Beyth Y.
    Primary peritoneal papillary serous adenocarcinoma: Clinical and management aspects. Gynecol Oncol 1991; 40: 230–6.
    OpenUrlPubMedWeb of Science
  6. 6.↵
    2. Recine MA,
    3. Deavers MT,
    4. Middleton LP,
    5. Silva EG,
    6. Malpica A.
    Serous carcinoma of the ovary and peritoneum with metastases to the breast and axillary lymph nodes: A potential pitfall. Am Surg Pathol. 2004; 28: 1646–51.
    OpenUrl
  7. 7.↵
    2. Kannerstein M,
    3. Churg J,
    4. McCaughey WT,
    5. Hill DP.
    Papillary tumors of the peritoneum in women: Mesothelioma or papillary carcinoma. Am J Obstet Gynecol. 1977; 127: 306–14.
    OpenUrlPubMed
  8. 8.↵
    2. Tsao SW,
    3. Mok CH,
    4. Knapp RC,
    5. Oike K,
    6. Muto MG,
    7. Welch WR, et al.
    Molecular genetic evidence of a unifocal origin for human serous ovarian carcinomas. Gynecol Oncol. 1993; 48: 5–10.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    2. Muto MG,
    3. Welch WR,
    4. Mok SC,
    5. Bandera CA,
    6. Fishbaugh PM,
    7. Tsao SW, et al.
    Evidence for a multifocal origin of papillary serous carcinoma of the peritoneum. Cancer Res. 1995; 55: 490–2.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    2. Piver MS,
    3. Eltabbakh GH,
    4. Hempling RE,
    5. Recio FO,
    6. Blumenson LE.
    Two sequential studies for primary peritoneal carcinoma: Induction with weekly cisplatin followed by either cisplatin-doxorubicin-cyclophosphamide or paclitaxel-cisplatin. Gynecol Oncol. 1997; 67: 141–6.
    OpenUrlPubMed
  11. 11.↵
    2. Khalifeh I,
    3. Deavers MT,
    4. Cristofanilli M,
    5. Coleman RL,
    6. Malpica A,
    7. Gilcrease MZ.
    Primary peritoneal serous carcinoma presenting as inflammatory breast cancer. Breast J. 2009; 15: 176–81.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    2. Signorelli M,
    3. Bogani G,
    4. Ditto A,
    5. Martinelli F,
    6. Chiappa V,
    7. Lopez C, et al.
    Risk-reducing surgery on the uterine adnexa: Timing and type of surgical treatment, and pathology report. Minerva ginecologica. 2016; 68: 536–43.
    OpenUrl
  13. 13.↵
    2. Ghezzi F,
    3. Uccella S,
    4. Cromi A,
    5. Bogani G,
    6. Donadello N,
    7. Riva C.
    Primary peritoneal cancer in lynch syndrome: A clinical-pathologic report of a case and analysis of the literature. Int J Gynecol Pathol. 2013; 32: 163–6.
    OpenUrl
  14. 14.↵
    2. Eltabbakh GH,
    3. Piver MS,
    4. Natarajan N,
    5. Mettlin CJ.
    Epidemiologic differences between women with extraovarian primary peritoneal carcinoma and women with epithelial ovarian cancer. Obstet Gynecol. 1998; 91: 254–9.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    2. Klein RL,
    3. Brown AR,
    4. Gomez-Castro CM,
    5. Chambers SK,
    6. Cragun JM,
    7. Grasso-Lebeau L, et al.
    Ovarian cancer metastatic to the breast presenting as inflammatory breast cancer: A case report and literature review. J Cancer. 2010; 1: 27–31.
    OpenUrlPubMedWeb of Science
  16. 16.↵
    2. Eltabbakh GH,
    3. Werness BA,
    4. Piver S,
    5. Blumenson LE.
    Prognostic factors in extraovarian primary peritoneal carcinoma. Gynecol Oncol. 1998; 71: 230–9.
    OpenUrlCrossRefPubMed
  17. 17.↵
    2. Attanoos RL,
    3. Webb R,
    4. Dojcinov SD,
    5. Gibbs AR.
    Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum. Histopathology. 2002; 40: 237–44.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.
    2. Kachali C,
    3. Eltoum I,
    4. Horton D,
    5. Chhieng DC.
    Use of mesothelin as a marker for mesothelial cells in cytologic specimens. Semin Diagn Pathol. 2006; 23: 20–4.
    OpenUrlCrossRefPubMed
  19. 19.↵
    2. Lee BH,
    3. Hecht JL,
    4. Pinkus JL,
    5. Pinkus GS.
    Wt1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids. Am J Clin Pathol. 2002; 117: 745–50.
    OpenUrlCrossRefPubMed
  20. 20.↵
    2. Laury AR,
    3. Hornick JL,
    4. Perets R,
    5. Krane JF,
    6. Corson J,
    7. Drapkin R, et al.
    Pax8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol. 2010; 34: 627–35.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    2. Ozsaran AA,
    3. Dikmen Y,
    4. Terek MC,
    5. Ulukus M,
    6. Ozdemir N,
    7. Orguc S, et al.
    Bilateral metastatic carcinoma of the breast from primary ovarian cancer. Arch Gynecol Obstet. 2000; 264: 166–7.
    OpenUrlCrossRefPubMed
  22. 22.
    2. Han L,
    3. Pansare V,
    4. Al-Abbadi M,
    5. Husain M,
    6. Feng J.
    Combination of muc5ac and wt-1 immunohistochemistry is useful in distinguishing pancreatic ductal carcinoma from ovarian serous carcinoma in effusion cytology. Diagn Cytopathol. 2010; 38: 333–6.
    OpenUrlPubMedWeb of Science
  23. 23.
    2. Albarracin CT,
    3. Jafri J,
    4. Montag AG,
    5. Hart J,
    6. Kuan SF.
    Differential expression of MUC2 and MUC5AC mucin genes in primary ovarian and metastatic colonic carcinoma. Human pathology. 2000; 31: 672–7.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    2. Dong L,
    3. Cui H,
    4. Li XP,
    5. Sun LF,
    6. Chang XH,
    7. Liang XD, et al.
    Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: A retrospective study of 273 patients. Zhonghua Fu Chan Ke Za Zhi. 2008; 43: 5–8.
    OpenUrlPubMed
  25. 25.↵
    2. Asch-Kendrick R,
    3. Cimino-Mathews A.
    The role of gata3 in breast carcinomas: A review. Hum pathol. 2016; 48: 37–47.
    OpenUrl
  26. 26.↵
    2. Shield PW,
    3. Papadimos DJ,
    4. Walsh MD.
    Gata3: A promising marker for metastatic breast carcinoma in serous effusion specimens. Cancer cytopathol. 2014; 122: 307–12.
    OpenUrlPubMed
  27. 27.↵
    2. Bhargava R,
    3. Beriwal S,
    4. Dabbs DJ.
    Mammaglobin vs GCDFP-15: An immunohistologic validation survey for sensitivity and specificity. Am J Clin Pathol. 2007; 127: 103–13.
    OpenUrlCrossRefPubMed
  28. 28.↵
    2. Wick MR,
    3. Lillemoe TJ,
    4. Copland GT,
    5. Swanson PE,
    6. Manivel JC,
    7. Kiang DT.
    Gross cystic disease fluid protein-15 as a marker for breast cancer: Immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin. Hum pathol. 1989; 20: 281–7.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    2. Krings G,
    3. Nystrom M,
    4. Mehdi I,
    5. Vohra P,
    6. Chen YY.
    Diagnostic utility and sensitivities of gata3 antibodies in triple-negative breast cancer. Hum pathol. 2014; 45: 2225–32.
    OpenUrl
  30. 30.↵
    2. Bayrak R,
    3. Haltas H,
    4. Yenidunya S.
    The value of cdx2 and cytokeratins 7 and 20 expression in differentiating colorectal adenocarcinomas from extraintestinal gastrointestinal adenocarcinomas: Cytokeratin 7-/20+ phenotype is more specific than cdx2 antibody. Diagn Pathol 2012; 7: 9.
    OpenUrlCrossRefPubMed
  31. 31.↵
    2. Duffy MJ.
    Carcinoembryonic antigen as a marker for colorectal cancer: Is it clinically useful? Clin Chem. 2001; 47: 624–30.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    2. Cedrone A,
    3. Covino M,
    4. Caturelli E,
    5. Pompili M,
    6. Lorenzelli G,
    7. Villani MR, et al.
    Utility of alpha-fetoprotein (afp) in the screening of patients with virus-related chronic liver disease: Does different viral etiology influence afp levels in hcc? A study in 350 western patients. Hepatogastroenterology. 2000; 47: 1654–8.
    OpenUrlPubMed
  33. 33.↵
    2. Waldstrom M,
    3. Grove A.
    Immunohistochemical expression of wilms tumor gene protein in different histologic subtypes of ovarian carcinomas. Arch Pathol Lab Med 2005; 129: 85–8.
    OpenUrlPubMed
  34. 34.↵
    2. Yang L,
    3. Han Y,
    4. Suarez Saiz F,
    5. Minden MD.
    A tumor suppressor and oncogene: The WT1 story. Leukemia. 2007; 21: 868–76.
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    2. Nakatsuka S,
    3. Oji Y,
    4. Horiuchi T,
    5. Kanda T,
    6. Kitagawa M,
    7. Takeuchi T, et al.
    Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol. 2006; 19: 804–14.
    OpenUrlPubMedWeb of Science
  36. 36.↵
    2. Liu Z,
    3. Yamanouchi K,
    4. Ohtao T,
    5. Matsumura S,
    6. Seino M,
    7. Shridhar V, et al.
    High levels of Wilms’ tumor 1 (WT1) expression were associated with aggressive clinical features in ovarian cancer. Anticancer Res. 2014; 34: 2331–40.
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    2. Srivastava A,
    3. Fuchs B,
    4. Zhang K,
    5. Ruan M,
    6. Halder C,
    7. Mahlum E, et al.
    High wt1 expression is associated with very poor survival of patients with osteogenic sarcoma metastasis. Clin Cancer Res. 2006; 12: 4237–43.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    2. Chivukula M,
    3. Niemeier LA,
    4. Edwards R,
    5. Nikiforova M,
    6. Mantha G,
    7. McManus K, et al.
    Carcinomas of distal fallopian tube and their association with tubal intraepithelial carcinoma: Do they share a common “precursor” lesion? Loss of heterozygosity and immunohistochemical analysis using pax 2, wt-1, and p53 markers. ISRN Obstet Gynecol. 2011; 2011: 858647.
    OpenUrlPubMed
  39. 39.↵
    2. Rackley RR,
    3. Flenniken AM,
    4. Kuriyan NP,
    5. Kessler PM,
    6. Stoler MH,
    7. Williams BR.
    Expression of the Wilms' tumor suppressor gene WT1 during mouse embryogenesis. Cell Growth Differ. 1993; 4: 1023–31.
    OpenUrlAbstract
  40. 40.↵
    2. Hylander B,
    3. Repasky E,
    4. Shrikant P,
    5. Intengan M,
    6. Beck A,
    7. Driscoll D, et al.
    Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer. Gynecol Oncol. 2006; 101: 12–7.
    OpenUrlCrossRefPubMed
  41. 41.↵
    2. Batlevi CL,
    3. Matsuki E,
    4. Brentjens RJ,
    5. Younes A.
    Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol. 2015; 13: 25–40.
    OpenUrl
  42. 42.↵
    2. Lengyel E,
    3. Burdette JE,
    4. Kenny HA,
    5. Matei D,
    6. Pilrose J,
    7. Haluska P, et al.
    Epithelial ovarian cancer experimental models. Oncogene. 2014; 33: 3619–33.
    OpenUrlCrossRefPubMed
  43. 43.↵
    2. Burleson KM,
    3. Hansen LK,
    4. Skubitz AP.
    Ovarian carcinoma spheroids disaggregate on type i collagen and invade live human mesothelial cell monolayers. Clin Exp Metastasis. 2004; 21: 685–97.
    OpenUrlCrossRefPubMedWeb of Science
  44. 44.↵
    2. Heyer J,
    3. Kwong LN,
    4. Lowe SW,
    5. Chin L.
    Non-germline genetically engineered mouse models for translational cancer research. Nat Rev Cancer. 2010; 10: 470–80.
    OpenUrlCrossRefPubMedWeb of Science
  45. 45.↵
    2. Barua A,
    3. Bitterman P,
    4. Abramowicz JS,
    5. Dirks AL,
    6. Bahr JM,
    7. Hales DB, et al.
    Histopathology of ovarian tumors in laying hens: A preclinical model of human ovarian cancer. Int J Gynecol Cancer. 2009; 19: 531–9.
    OpenUrlCrossRefPubMed
  46. 46.↵
    2. Gao F,
    3. Shen XZ,
    4. Jiang F,
    5. Wu Y,
    6. Han C.
    DNA-guided genome editing using the natronobacterium gregoryi argonaute. Nat biotechnol. 2016; 34: 768–73.
    OpenUrl
  47. 47.↵
    2. Mhawech-Fauceglia P,
    3. Kay B,
    4. Li CJ,
    5. Lin YG.
    Metastatic ovarian papillary serous carcinoma to the breast: Diagnosis and pitfalls. Gynecol Oncol Case Rep. 2013; 4: 35–7.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords